Cancer Treatment Reviews
Volume 31, Issue 6 , Pages 423-438, October 2005

Papillary thyroid microcarcinoma: A surgical perspective

  • George H. Sakorafas

      Affiliations

    • Department of Surgery, 251 Hellenic Air Force Hospital, Arkadias 19-21, GR-11526 Athens, Greece
    • Corresponding Author InformationCorresponding author. Tel.: +30 210 74 87 318; fax: + 30 210 74 87 192.
  • ,
  • John Giotakis

      Affiliations

    • Department of Otorinholaryngology, Medical School, Athens University, Athens, Greece
  • ,
  • Vania Stafyla

      Affiliations

    • Department of Surgery, 251 Hellenic Air Force Hospital, Arkadias 19-21, GR-11526 Athens, Greece

published online 07 July 2005.

Summary 

Papillary thyroid microcarcinoma (PTMC) is defined as a papillary thyroid cancer measuring less than 10mm in its greatest diameter. It is the most common form of thyroid cancer, detected in up to 36% in autopsy studies. The wide availability and use of neck ultrasonography in the evaluation of carotid arteries and of the thyroid resulted in an increased detection of PTMC. PTMC is often multifocal. The diagnosis is usually based on a combination of clinical examination, laboratory investigations, and specialized radiological techniques (mainly neck ultrasonography combined with fine-needle aspiration cytology). A common scenario is the diagnosis of PTMC as an incidental finding following thyroidectomy for a presumably benign thyroid disease. Despite some controversy, most authors agree that PTMC should be treated by total or near-total thyroidectomy, provided it can be performed safely. Because of its many and major advantages, in our clinical practice, total or near-total thyroidectomy is the procedure of choice for the management of PTMC. Given the high incidence of PTMC as an incidental finding and the frequent multifocality, we also favor total or near-total thyroidectomy for the surgical management of nodular thyroid disease (multinodular goiter or dominant presumably benign thyroid nodule/s). Despite some controversy, we perform central neck lymph node dissection electively, in the presence of cervical lymphadenopathy. Radioiodine ablation therapy may be used as an adjuvant therapy. Prognostic factors (such as tumor multicentricity, positive lymph nodes, capsular or vascular invasion) or scoring systems (such as the AMES) can be used to select patients for radioiodine adjuvant therapy. Suppression therapy is needed after surgical management. Despite the potential for neck lymph node and even distant metastases, the biological behavior of PTMC is in general benign and the prognosis is very good.

Keywords: Thyroid, Cancer, Papillary, Surgery, Lymph node dissection, Radioiodine therapy, Suppression therapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0305-7372(05)00083-6

doi:10.1016/j.ctrv.2005.04.009

Cancer Treatment Reviews
Volume 31, Issue 6 , Pages 423-438, October 2005